Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

d to Topical Interferon Alpha-2b reflect additional costs in preparation to open additional sites in Germany for the AGW clinical trial and the expected Phase IIb/III IND/CTA filings for LSIL to occur before the end of the Company's fiscal fourth quarter ending July 31, 2009.

Operating, general and administration expenses in fiscal 2008 totaled $4,757,000 and represent an increase of $339,000 or 7.7% when compared to fiscal 2007. Operating, general and administration expenses reflect higher audit and consulting fees and a one time charge of $434,000 relating to the resignation of the Company's Chairman. Offsetting these cost were lower marketing promotional costs and legal fees associated with the 2008 Annual General Meeting.

Amortization of intangible assets in fiscal 2008 totaled $16,000 and represented a decrease of $143,000 when compared to fiscal 2007. Certain intangible assets were fully amortized in fiscal 2007 and prior, resulting in the lower amortization expense in fiscal 2008 and on a go forward basis. Amortization of capital assets in fiscal 2008 decreased marginally when compared to fiscal 2007.

Stock-based compensation expense in fiscal 2008 totaled $44,000 and represents a decrease of $3,000 when compared to fiscal 2007. The Company did not issue any stock options in fiscal 2008 and the stock-based compensation expense during the year represents the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.

Interest income totaled $645,000 in fiscal 2008 and $496,000 in 2007. The increase is mainly the result of higher on hand cash balances in fiscal 2008 versus fiscal 2007.

The Company realized a foreign exchange gain of $327,000 in fiscal 2008, which compares favorably to the foreign exchange gain of $9,000 which was realized in fiscal 2007. The Canadian dollar's strength over the last three fiscal years has moderated in fiscal 2008 and was range bound while the
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... PORTLAND, Oregon , August 4, 2015 /PRNewswire/ ... published by Allied Market Research, titled, "World Cardiac ... global cardiac biomarker market would generate the revenue ... of 18.9% from 2015 to 2020. Cardiac Troponins ... throughout the forecast period due to high sensitivity ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... diagnostic tests – today announced that Robert A. Gregg, PhD, has joined RPS ... than 30 years of relevant experience and remarkable achievements in the medical device ...
(Date:8/4/2015)... Aug. 4, 2015  Blueprint Medicines (NASDAQ: BPMC ... kinase drugs for genomically defined diseases, today announced that ... a company overview at the 2015 Wedbush PacGrow Healthcare ... EDT. A live webcast of the event ... the Blueprint Medicines website at www.blueprintmedicines.com . An ...
(Date:8/4/2015)... Francisco, CA (PRWEB) , ... August 04, 2015 , ... ... difference by inviting a diverse selection of entrepreneurs from across the United States to ... CEO Jessica Richman is honored to be chosen to be among the attendees. , ...
Breaking Biology Technology:Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2
... Electronic health record systems generally are perceived to have ... more clinics consider moving from paper charts to EHR ... barriers to entry. , ,The evolution of systems for ... robust data security has prompted more hospitals and ...
... - Just six weeks after taking the helm at ... to pursue opportunities in the private sector, the organization announced. ... has served as general counsel to WiCell's parent, the ... high-tech and biotechnology industries. , ,Donley, who joined WARF in ...
... An education research team at the University of Wisconsin-Madison ... to study the impact of digital media on youth ... investment will support 24 national studies of different aspects of ... , ,"What MacArthur is actually trying to do, with this ...
Cached Biology Technology:GE Healthcare launches hybrid electronic record 2Donley resigns as WiCell director 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a form of breast cancer known as estrogen receptor positive ... the treatment and prevention of recurring breast cancer. Currently, ... dose is prescribed for every patient. New research at ... patient-specific genetic factors, lack of exposure to vitamin D during ...
... DNA code for a complex region of the human genome ... Fraser University, chart new territory in immunity research. , They ... how well they operate and, potentially, what they fight off, ... drugs, treatments and vaccinations are designed to treat whole populations ...
... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... study of seven missense variants of the BRCA1 gene ... to the risk of suffering breast or ovarian cancer. ... PLoS One The classification of these three ...
Cached Biology News:Cold winters freezing out breast cancer treatment 2Scientists find ethnicity linked to antibodies 2Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene 2
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Biology Products: